Sirnaomics (FRA:V5Z) Total Liabilities: €38.51 Mil (As of Dec. 2025)


FRA:V5Z Sirnaomics Ltd FRA:V5Z
26 GF Score
Price €0.48
! 4 Warning Signs
View Full Analysis

What is Sirnaomics Total Liabilities?

Sirnaomics FRA:V5Z 26 Total Liabilities is €38.51 Mil as of Dec. 2025. GuruFocus rates FRA:V5Z with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Sirnaomics's Total Liabilities for the quarter that ended in Dec. 2025 was €38.51 Mil.

Sirnaomics's quarterly Total Liabilities declined from Dec. 2024 (€42.34 Mil) to Jun. 2025 (€35.03 Mil) but then increased from Jun. 2025 (€35.03 Mil) to Dec. 2025 (€38.51 Mil).

Sirnaomics's annual Total Liabilities declined from Dec. 2023 (€47.07 Mil) to Dec. 2024 (€42.34 Mil) and declined from Dec. 2024 (€42.34 Mil) to Dec. 2025 (€38.51 Mil).

Sirnaomics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sirnaomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirnaomics Total Liabilities Chart

Sirnaomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 26.87 49.44 47.07 42.34 38.51

Sirnaomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.07 48.68 42.34 35.03 38.51
FRA:V5Z
26GF Score
Sirnaomics Ltd FRA:V5Z
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sirnaomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sirnaomics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=32.601+(5.911+0.00099999999999945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=38.51

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=17.597--20.916
=38.51

Sirnaomics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=32.601+(5.911+0.00099999999999945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=38.51

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=17.597--20.916
=38.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €38.51 Mil mean?
Sirnaomics (FRA:V5Z) has a Total Liabilities of €38.51 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sirnaomics and its competitors.
Is Sirnaomics' Total Liabilities too high?
Sirnaomics' current Total Liabilities is €38.51 Mil. Overall, Sirnaomics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sirnaomics' Total Liabilities compare to VRTX and REGN?
Sirnaomics' Total Liabilities of €38.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sirnaomics and its competitors. Sirnaomics's current Total Liabilities is €38.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirnaomics stock overvalued right now?
Sirnaomics (FRA:V5Z) has a current Total Liabilities of €38.51 Mil. The current Total Liabilities is €38.51 Mil. Sirnaomics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sirnaomics (FRA:V5Z), the current Total Liabilities is €38.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirnaomics Business Description

Other Exchanges 02257:Hong Kong
Address No.218 Xinghu Street, Unit 415, A4 Building, Suzhou Industrial Park, Suzhou, CHN
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China. All of the company's revenue is derived from the mainland of the People's Republic of China (the PRC). The pipeline includes: STP705, STP707, STP355, STP369, STP705, STP122G, STP125G, and STP144G.
26GF Score

Get the complete analysis for FRA:V5Z

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price